RAPT Therapeutics Company Insiders

RAPT Stock  USD 1.13  0.04  3.42%   
Slightly above 80 percent of RAPT Therapeutics' insiders are selling. The analysis of the overall insider sentiment regarding RAPT Therapeutics suggests that a fairly large number of insiders are terrified. RAPT Therapeutics employs about 70 people. The company is managed by 12 executives with a total tenure of roughly 164 years, averaging almost 13.0 years of service per executive, having 5.83 employees per reported executive.

Insider Sentiment 20

 Mostly Selling

 
Selling
 
Buying

Latest Trades

2024-01-05Dirk G BrockstedtDisposed 898 @ 22.78View
2023-12-21William HoDisposed 2500 @ 21.68View
2023-11-28William HoDisposed 1500 @ 13.72View
2023-10-03William HoDisposed 2500 @ 15.77View
2023-08-18William HoDisposed 2500 @ 18.92View
2023-04-19William HoDisposed 5000 @ 18.88View
2023-03-14Wendye RobbinsAcquired 2500 @ 18.99View
2023-03-07William HoDisposed 5000 @ 29.62View
2023-01-24William HoDisposed 5000 @ 30View
2023-01-19William HoDisposed 5000 @ 25.56View
2023-01-05Dirk G BrockstedtDisposed 742 @ 21.97View
2022-12-29William HoDisposed 5000 @ 18.03View
2022-11-28William HoDisposed 5000 @ 17.87View
2022-11-02William HoDisposed 5000 @ 22.32View
2022-10-13William HoDisposed 2000 @ 21.52View
2022-08-30William HoDisposed 2500 @ 28.13View
2022-07-11William HoDisposed 2000 @ 19.95View
2022-05-25Group Ii Lp ColumnAcquired 1900 @ 12.45View
2022-05-23Group Ii Lp ColumnAcquired 10236 @ 12.5View
2022-05-10Group Ii Lp ColumnAcquired 1250000 @ 10.67View
Monitoring RAPT Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in RAPT Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
For more information on how to buy RAPT Stock please use our How to Invest in RAPT Therapeutics guide.

RAPT Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.4658) % which means that it has lost $0.4658 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8013) %, meaning that it created substantial loss on money invested by shareholders. RAPT Therapeutics' management efficiency ratios could be used to measure how well RAPT Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.64 in 2025. Return On Capital Employed is likely to drop to -0.79 in 2025. Total Current Liabilities is likely to gain to about 26.4 M in 2025, whereas Liabilities And Stockholders Equity is likely to drop slightly above 151.1 M in 2025.
Common Stock Shares Outstanding is likely to drop to about 27.7 M in 2025. Net Loss is likely to drop to about (79.2 M) in 2025

RAPT Therapeutics Workforce Comparison

RAPT Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 2,119. RAPT Therapeutics holds roughly 70.0 in number of employees claiming about 3% of equities under Health Care industry.

RAPT Therapeutics Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific RAPT Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on RAPT Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, RAPT Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

RAPT Therapeutics Notable Stakeholders

A RAPT Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as RAPT Therapeutics often face trade-offs trying to please all of them. RAPT Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting RAPT Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Brian MDPresident CEOProfile
Gwen CarscaddenChief OfficerProfile
Rodney YoungPrincipal CFOProfile
David WustrowSenior DevelopmentProfile
William HoChief OfficerProfile
Jennifer NicholsonSenior AssuranceProfile
Michael ListgartenGeneral CounselProfile
William MDChief OfficerProfile
Steve YoungVice TechnologyProfile
Paul KassnerSenior BiologyProfile
Nipun MBASenior OperationsProfile
Dirk BrockstedtChief OfficerProfile

About RAPT Therapeutics Management Performance

The success or failure of an entity such as RAPT Therapeutics often depends on how effective the management is. RAPT Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of RAPT management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the RAPT management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.61)(0.64)
Return On Capital Employed(0.75)(0.79)
Return On Assets(0.61)(0.64)
Return On Equity(0.91)(0.87)
Please note, the imprecision that can be found in RAPT Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of RAPT Therapeutics. Check RAPT Therapeutics' Beneish M Score to see the likelihood of RAPT Therapeutics' management manipulating its earnings.

RAPT Therapeutics Workforce Analysis

Traditionally, organizations such as RAPT Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare RAPT Therapeutics within its industry.

RAPT Therapeutics Manpower Efficiency

Return on RAPT Therapeutics Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee1.7M
Net Loss Per Executive9.7M
Working Capital Per Employee2M
Working Capital Per Executive11.7M

Additional Tools for RAPT Stock Analysis

When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.